340 related articles for article (PubMed ID: 23123106)
21. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.
Visan L; Rouleau N; Proust E; Peyrot L; Donadieu A; Ochs M
Hum Vaccin Immunother; 2018 Feb; 14(2):489-494. PubMed ID: 29135332
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
[TBL] [Abstract][Full Text] [Related]
23. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
24. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.
Odutola A; Ota MO; Ogundare EO; Antonio M; Owiafe P; Worwui A; Greenwood B; Alderson M; Traskine M; Verlant V; Dobbelaere K; Borys D
Hum Vaccin Immunother; 2016; 12(2):393-402. PubMed ID: 26618243
[TBL] [Abstract][Full Text] [Related]
25. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.
Berglund J; Vink P; Tavares Da Silva F; Lestrate P; Boutriau D
Clin Vaccine Immunol; 2014 Jan; 21(1):56-65. PubMed ID: 24173029
[TBL] [Abstract][Full Text] [Related]
26. Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia.
Hagerman A; Posfay-Barbe KM; Grillet S; Ochs MM; Brookes RH; Greenberg D; Givon-Lavi N; Dagan R; Siegrist CA
Clin Microbiol Infect; 2012 Aug; 18(8):756-62. PubMed ID: 21851490
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial.
Entwisle C; Hill S; Pang Y; Joachim M; McIlgorm A; Colaco C; Goldblatt D; De Gorguette D'Argoeuves P; Bailey C
Vaccine; 2017 Dec; 35(51):7181-7186. PubMed ID: 29132988
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.
Glenn GM; Smith G; Fries L; Raghunandan R; Lu H; Zhou B; Thomas DN; Hickman SP; Kpamegan E; Boddapati S; Piedra PA
Vaccine; 2013 Jan; 31(3):524-32. PubMed ID: 23153449
[TBL] [Abstract][Full Text] [Related]
30. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
[TBL] [Abstract][Full Text] [Related]
31. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
[TBL] [Abstract][Full Text] [Related]
34. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.
Harro CD; Betts RF; Hartzel JS; Onorato MT; Lipka J; Smugar SS; Kartsonis NA
Vaccine; 2012 Feb; 30(9):1729-36. PubMed ID: 22192849
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
[TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
